Dataset from A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

The purpose of this study is to provide continued access of ixazomib and/or other study
medications and to continue collecting relevant safety data to monitor participant's safety,
determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital
organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice
of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic
light chain (AL) amyloidosis.